Insiders · GNLX

GNLX insider transactions

Genelux Corporation (GNLX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for GNLX

• 6d
  Head of Regulatory Smalling Ralph sold $563 worth of shares (192 units at $2.93), decreasing direct ownership by 0.28% to 67,611 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 8d
  Director Thomas John sold $29,801 worth of shares (10,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 472,784 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 29d
  Chief Technical Officer Cappello Joseph sold $1,799 worth of shares (605 units at $2.97), decreasing direct ownership by 0.39% to 154,549 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 29d
  Chief Scientific Officer Yu Yong sold $1,798 worth of shares (605 units at $2.97), decreasing direct ownership by 0.40% to 149,706 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 29d
  Head of Regulatory Smalling Ralph sold $804 worth of shares (270 units at $2.98), decreasing direct ownership by 0.40% to 67,803 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 29d
  President and CEO Zindrick Thomas sold $8,226 worth of shares (2,798 units at $2.94), decreasing direct ownership by 0.52% to 532,051 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 76d
  SEC Form 4 filed by Zindrick Thomas

  4 - GENELUX Corp (0001231457) (Issuer)
• 76d
  SEC Form 4 filed by Smalling Ralph

  4 - GENELUX Corp (0001231457) (Issuer)
• 76d
  SEC Form 4 filed by Yu Yong

  4 - GENELUX Corp (0001231457) (Issuer)
• 76d
  SEC Form 4 filed by Cappello Joseph

  4 - GENELUX Corp (0001231457) (Issuer)
• 99d
  Director Thomas John sold $28,957 worth of shares (10,000 units at $2.90), decreasing direct ownership by 2% to 482,784 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 154d
  SEC Form 4 filed by Chief Medical Officer Litten Jason

  4 - GENELUX Corp (0001231457) (Issuer)
• 154d
  SEC Form 3 filed by new insider Litten Jason

  3 - GENELUX Corp (0001231457) (Issuer)
• 181d
  President and CEO Zindrick Thomas sold $66,370 worth of shares (17,182 units at $3.86), decreasing direct ownership by 3% to 538,431 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 181d
  SVP, Clinical Development Yu Yong sold $16,032 worth of shares (4,192 units at $3.82), decreasing direct ownership by 3% to 145,844 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 181d
  Chief Technical Officer Cappello Joseph sold $14,361 worth of shares (3,706 units at $3.88), decreasing direct ownership by 2% to 156,060 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 183d
  Head of Regulatory Smalling Ralph sold $8,740 worth of shares (2,332 units at $3.75), decreasing direct ownership by 3% to 68,658 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 190d
  Director Thomas John sold $50,008 worth of shares (10,000 units at $5.00), decreasing direct ownership by 2% to 492,784 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 280d
  SEC Form 4 filed by SVP, Clinical Development Yu Yong

  4 - GENELUX Corp (0001231457) (Issuer)
• 280d
  Head of Regulatory Smalling Ralph was granted 10,000 shares, increasing direct ownership by 16% to 70,990 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 280d
  SEC Form 4 filed by President and CEO Zindrick Thomas

  4 - GENELUX Corp (0001231457) (Issuer)
• 280d
  SEC Form 4 filed by Chief Technical Officer Cappello Joseph

  4 - GENELUX Corp (0001231457) (Issuer)
• 285d
  Director Thomas John was granted 22,283 shares, increasing direct ownership by 5% to 502,784 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 285d
  President and CEO Zindrick Thomas was granted 361,200 shares, increasing direct ownership by 187% to 554,161 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 285d
  Head of Regulatory Smalling Ralph was granted 26,230 shares, increasing direct ownership by 75% to 60,990 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 285d
  Director Mirabelli Mary was granted 22,283 shares, increasing direct ownership by 44% to 73,284 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 285d
  SVP, Clinical Development Yu Yong was granted 101,480 shares, increasing direct ownership by 209% to 150,036 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 285d
  Director Tyree James L was granted 22,283 shares, increasing direct ownership by 49% to 68,074 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 285d
  Director Smither John W was granted 22,283 shares, increasing direct ownership by 42% to 74,994 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 285d
  Chief Technical Officer Cappello Joseph was granted 107,500 shares, increasing direct ownership by 206% to 159,766 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 343d
  SEC Form 4 filed by General Counsel & Secretary Groen Eric

  4 - GENELUX Corp (0001231457) (Issuer)
• 343d
  SEC Form 3 filed by new insider Groen Eric

  3 - GENELUX Corp (0001231457) (Issuer)
• 351d
  Director Thomas John gifted 25,000 shares, decreasing direct ownership by 5% to 480,501 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 393d
  VP, Clinical Trial Operations Yu Yong sold $16,291 worth of shares (5,579 units at $2.92), decreasing direct ownership by 10% to 47,640 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 393d
  VP, Pharmaceutical Development Cappello Joseph sold $13,832 worth of shares (4,737 units at $2.92), decreasing direct ownership by 8% to 52,266 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 393d
  President and CEO Zindrick Thomas sold $31,431 worth of shares (10,764 units at $2.92), decreasing direct ownership by 5% to 191,447 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 393d
  General Counsel Ryder Sean sold $13,067 worth of shares (4,475 units at $2.92), decreasing direct ownership by 9% to 47,621 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 393d
  Head of Regulatory Smalling Ralph sold $3,676 worth of shares (1,259 units at $2.92), decreasing direct ownership by 3% to 34,760 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 419d
  Head of Regulatory Smalling Ralph was granted 4,172 shares, increasing direct ownership by 13% to 36,019 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 419d
  VP, Pharmaceutical Development Cappello Joseph was granted 13,350 shares, increasing direct ownership by 31% to 57,003 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 419d
  VP, Clinical Trial Operations Yu Yong was granted 13,350 shares, increasing direct ownership by 33% to 53,219 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 419d
  General Counsel Ryder Sean was granted 10,708 shares, increasing direct ownership by 26% to 52,096 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 419d
  President and CEO Zindrick Thomas was granted 30,339 shares, increasing direct ownership by 18% to 202,211 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 492d
  SEC Form 4 filed by Chief Financial Officer Pulisic Matthew

  4 - GENELUX Corp (0001231457) (Issuer)
• 492d
  SEC Form 3 filed by new insider Pulisic Matthew

  3 - GENELUX Corp (0001231457) (Issuer)
• 526d
  Amendment: SEC Form 4 filed by Director Mirabelli Mary

  4/A - GENELUX Corp (0001231457) (Issuer)
• 526d
  Amendment: SEC Form 4 filed by Director Tyree James L

  4/A - GENELUX Corp (0001231457) (Issuer)
• 526d
  Amendment: SEC Form 4 filed by Director Smither John W

  4/A - GENELUX Corp (0001231457) (Issuer)
• 526d
  Amendment: SEC Form 4 filed by Director Thomas John

  4/A - GENELUX Corp (0001231457) (Issuer)
• 527d
  Director Tyree James L sold $8,512 worth of shares (3,460 units at $2.46), decreasing direct ownership by 7% to 45,791 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 537d
  Head of Regulatory Smalling Ralph was granted 15,525 shares, increasing direct ownership by 95% to 31,847 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 537d
  General Counsel Ryder Sean was granted 22,000 shares, increasing direct ownership by 113% to 41,388 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 537d
  VP, Clinical Trial Operations Yu Yong was granted 29,000 shares, increasing direct ownership by 267% to 39,869 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 537d
  VP, Pharmaceutical Development Cappello Joseph was granted 29,000 shares, increasing direct ownership by 198% to 43,653 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 537d
  Chief Financial Officer Zak Lourie S. was granted 41,650 shares, increasing direct ownership by 102% to 82,452 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 537d
  President and CEO Zindrick Thomas was granted 134,500 shares, increasing direct ownership by 360% to 171,872 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 539d
  Head of Regulatory Smalling Ralph sold $5,873 worth of shares (2,510 units at $2.34), decreasing direct ownership by 13% to 16,322 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 539d
  President and CEO Zindrick Thomas sold $33,497 worth of shares (14,315 units at $2.34), decreasing direct ownership by 28% to 37,372 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 539d
  Chief Financial Officer Zak Lourie S. sold $4,921 worth of shares (2,103 units at $2.34), decreasing direct ownership by 5% to 40,802 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)
• 539d
  VP, Pharmaceutical Development Cappello Joseph sold $14,742 worth of shares (6,300 units at $2.34), decreasing direct ownership by 30% to 14,653 units (SEC Form 4)

  4 - GENELUX Corp (0001231457) (Issuer)